Hejna M - Search Results

1

Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract.

Hejna M, Hamilton G, Brodowicz T, Haberl I, Fiebiger WC, Scheithauer W, Virgolini I, Köstler WJ, Oberhuber G, Raderer M. Hejna M, et al. Anticancer Res. 2001 Mar-Apr;21(2A):1183-7. Anticancer Res. 2001. PMID: 11396161

2

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.

Raderer M, Kurtaran A, Hejna M, Vorbeck F, Angelberger P, Scheithauer W, Virgolini I. Raderer M, et al. Among authors: hejna m. Br J Cancer. 1998 Jul;78(1):1-5. doi: 10.1038/bjc.1998.433. Br J Cancer. 1998. PMID: 9662242 Free PMC article.

3

Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.

Raderer M, Kurtaran A, Yang Q, Meghdadi S, Vorbeck F, Hejna M, Angelberger P, Kornek G, Pidlich J, Scheithauer W, Virgolini I. Raderer M, et al. Among authors: hejna m. J Nucl Med. 1998 Sep;39(9):1570-5. J Nucl Med. 1998. PMID: 9744345 Free article.

4

Association between Helicobacter pylori infection and pancreatic cancer.

Raderer M, Wrba F, Kornek G, Maca T, Koller DY, Weinlaender G, Hejna M, Scheithauer W. Raderer M, et al. Among authors: hejna m. Oncology. 1998 Jan-Feb;55(1):16-9. doi: 10.1159/000011830. Oncology. 1998. PMID: 9428370

5

Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.

Hejna M, Kornek GV, Raderer M, Depisch D, Brodowicz T, Fiebiger WC, Scheithauer W. Hejna M, et al. Br J Cancer. 1998 Sep;78(6):760-4. doi: 10.1038/bjc.1998.574. Br J Cancer. 1998. PMID: 9743296 Free PMC article.

6

Nonsurgical management of malignant thymoma.

Hejna M, Haberl I, Raderer M. Hejna M, et al. Cancer. 1999 May 1;85(9):1871-84. Cancer. 1999. PMID: 10223225 Review.

7

Resveratrol pretreatment desensitizes AHTO-7 human osteoblasts to growth stimulation in response to carcinoma cell supernatants.

Ulsperger E, Hamilton G, Raderer M, Baumgartner G, Hejna M, Hoffmann O, Mallinger R. Ulsperger E, et al. Among authors: hejna m. Int J Oncol. 1999 Nov;15(5):955-9. doi: 10.3892/ijo.15.5.955. Int J Oncol. 1999. PMID: 10536179

8

Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.

Hejna M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger WC, Marosi L, Schneeweiss B, Greul R, Scheithauer W. Hejna M, et al. Cancer. 2000 Aug 1;89(3):516-22. Cancer. 2000. PMID: 10931450 Clinical Trial.

9

Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.

Hejna M, Köstler WJ, Raderer M, Tomek S, Brodowicz T, Scheithauer W, Wiltschke C, Zielinski CC. Hejna M, et al. Anticancer Drugs. 2000 Sep;11(8):629-34. doi: 10.1097/00001813-200009000-00005. Anticancer Drugs. 2000. PMID: 11081454 Clinical Trial.

10

Soluble ICAM-1 in breast cancer: clinical significance and biological implications.

Köstler WJ, Tomek S, Brodowicz T, Budinsky AC, Flamm M, Hejna M, Krainer M, Wiltschke C, Zielinski CC. Köstler WJ, et al. Among authors: hejna m. Cancer Immunol Immunother. 2001 Nov;50(9):483-90. doi: 10.1007/s002620100223. Cancer Immunol Immunother. 2001. PMID: 11761443 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters